Eli Lilly and Company

Anne H Dantzig

Stuart W Bright

Linda B Tabas

Robert L Hamill

Manuel Debono

Raymond C Yao

Mark Alan Winter

R Michael Molloy

James J Starling

Dennis R Berry

Srinivasan Chandrasekhar

Robert L Shepard

Paul Luther Skatrud

Jo Ann Hoskins

James Allen Monn

Maria Angeles Martinez-Grau

Concepcion Pedregal-Tercero

Ana Belen Bueno Melendo

Stephanie Ann Sweetana

Alfonso De Dios

Luisa Maria Martin-Cabrejas

Jose Alfredo Martin

Carlos Montero Salgado

Carmen Dominguez-Fernandez

Marc Francis Herin

This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.

Prodrugs of excitatory amino acids

Monoclonal antibodies which react with the human influx peptide transporter are provided. The human influx peptide transporter-reactive antibodies are useful in the purification of influx peptide transporter and in immunoassays to identify agents taken up into the cell by the human influx peptide transporter mechanism.

Immunomethods for isolating and indentifying human influx peptide transporter

The present invention provides methods for reversing multidrug resistance in a resistant neoplasm by treating a mammal in need of said treatment with a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene. This invention also provides methods for treating neoplasms in a mammal which comprises administering to a mammal in need of this treatment a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene in combination with an oncolytic agent.

Methods for treating resistant tumors

Methods for reversing multidrug resistance

Monoclonal antibodies which react with the human influx peptide transporter are provided. The human influx peptide transporter-reactive antibodies are useful in the purification of influx peptide transporter and in immunoassays to identify agents taken up into the cell by the human influx peptide transporter mechanism. The monoclonal antibodies are also useful for the detection and treatment of carcinomas derived from the gastrointestinal tract and pancreatic duct.

Diagnosis of colon carcinoma using monoclonal antibodies to human influx

Monoclonal antibodies to human influx peptide transporter

The present invention provides isolated DNA compounds and recombinant DNA vectors that encode mammalian influx peptide transporter activity. The invention also provides host cells transformed with these vectors and a method for production of mammalian influx peptide transporter activity by recombinant DNA techniques. The invention also provides a method for identifying compounds that are transported into the cell by the influx peptide transporter.

Mammalian influx peptide transporter

Fermentation product A87689 is produced by a strain of Amycolatopsis mediterranei selected from NRRL 18815 and NRRL 18851, or an A87689-producing mutant thereof. A87689, its C.sub.1-6 -alkyl ether and C.sub.1-6 -alkanoyl ester derivatives and pharmaceutically acceptable salts thereof are phospholipase A.sub.2 inhibitors that are useful as antiinflammatory agents. Fermentation products known as BU-3889V, its components and pharmaceutically acceptable salts thereof, are phospholipase A.sub.2 inhibitors that are also useful as antiinflammatory agents.

A87689 compounds

A87689 compounds employed as a phospholipase A.sub.2 (PLA.sub.2)

Amycolatopsis mediterranei strains useful to prepare A87689 compounds

Growing community of inventors

Crawfordsville, IN, United States of America

Anne H Dantzig